| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $2,414,757 ) |
| | 2026 | 2026 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | RM1DA064499 | A patient preference trial of sublingual versus extended-release buprenorphine telemedicine and pharmacy linkage for individuals re-entering the community from jail | 000 | 2 | NIH | 6/23/2026 | $1,442,966 |
| | 2026 | 2026 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R33DA059033 | Implementing a patient navigation intervention across a health system to improve outcomes for patients with opioid use disorder | 001 | 3 | NIH | 8/27/2026 | $1,118,323 |
| | 2026 | 2026 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R61DA064704 | Empowering Support Persons to Enhance the Recovery Capital of Postpartum Women with Opioid Use Disorder | 000 | 1 | NIH | 3/27/2026 | $448,565 |
| | 2026 | 2026 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R21DA062508 | Leveraging a time-limited opportunity to study the impact of an intervention for individuals bereaved by drug overdose | 000 | 2 | NIH | 2/5/2026 | $236,700 |
| | 2026 | 2026 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057608 | Treating Polysubstance Use in Methadone Maintenance: Application of Novel Digital Technology | 001 | 3 | NIH | 7/21/2026 | $761,851 |
| | 2026 | 2026 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01NR021987 | A Patient Navigation Trial for Housing and Health (PATHH): A randomized controlled trial | 001 | 2 | NIH | 7/20/2026 | $759,043 |
| | 2026 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056888 | Optimizing PrEP Implementation and Cost-effectiveness among Individuals with a Substance Use Disorder | 001 | 4 | NIH | 4/1/2026 | -$901,066 |
| | 2026 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R34DA059770 | Addressing racial disparities in opioid overdose deaths using an open source peer recovery coach training and multimodal mobile health platform | 003 | 2 | NIH | 7/28/2026 | $0 |
| | 2026 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R34DA059770 | Addressing racial disparities in opioid overdose deaths using an open source peer recovery coach training and multimodal mobile health platform | 000 | 2 | NIH | 7/2/2026 | $0 |
| | 2026 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R33DA059033 | Implementing a patient navigation intervention across a health system to improve outcomes for patients with opioid use disorder | 000 | 2 | NIH | 11/20/2025 | $0 |
| | 2026 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UM1DA064499 | A patient preference trial of sublingual versus extended-release buprenorphine telemedicine and pharmacy linkage for individuals re-entering the community from jail | 001 | 1 | NIH | 4/22/2026 | $0 |
| | 2026 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UM1DA064499 | A patient preference trial of sublingual versus extended-release buprenorphine telemedicine and pharmacy linkage for individuals re-entering the community from jail | 000 | 1 | NIH | 12/23/2025 | $0 |
| | 2026 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA058674 | A comparative effectiveness trial of sublingual versus extended-release buprenorphine with individuals leaving a carceral setting | 000 | 3 | NIH | 6/26/2026 | $0 |
| | 2026 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056287 | Comparative- and cost-effectiveness research determining the optimal intervention for advancing individuals living with HIV to full viral suppression | 001 | 3 | NIH | 4/3/2026 | -$1,451,625 |
| | 2026 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056287 | Comparative- and cost-effectiveness research determining the optimal intervention for advancing individuals living with HIV to full viral suppression | 000 | 3 | NIH | 1/13/2026 | $0 |
| | 2026 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057685 | Identifying Suspected Drug Overdose Deaths in Near Real-Time Using Data Collected by Death Investigators | 001 | 2 | NIH | 6/29/2026 | $0 |
| | 2026 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057052 | Take-home expansion: Scope and impact study (THESIS) | 000 | 4 | NIH | 4/1/2026 | $0 |
| | 2026 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01NR021987 | A Patient Navigation Trial for Housing and Health (PATHH): A randomized controlled trial | 000 | 1 | NIH | 12/15/2025 | $0 |
| | 2026 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056888 | Optimizing PrEP Implementation and Cost-effectiveness among Individuals with a Substance Use Disorder | 000 | 4 | NIH | 1/13/2026 | $0 |
| | 2026 | 2024 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG3DA058305 | Continuing Care App for Justice-Involved Individuals with Substance Use Disorders | 001 | 2 | NIH | 8/25/2026 | $0 |
| | 2026 | 2024 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA045724 | Opioid Use Disorder Treatment Linkage at STD Clinics using Buprenorphine (OUTLAST-B) | 000 | 5 | NIH | 5/27/2026 | $0 |
| | 2026 | 2024 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG3DA058305 | Continuing Care App for Justice-Involved Individuals with Substance Use Disorders | 000 | 2 | NIH | 12/12/2025 | $0 |
| | 2026 | 2023 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG1DA050077 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 001 | 5 | NIH | 5/6/2026 | $0 |
| | 2026 | 2023 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG1DA050077 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 000 | 5 | NIH | 4/30/2026 | $0 |
| | 2026 | 2023 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R61DA059033 | Implementing a patient navigation intervention across a health system to address treatment entry inequities | 000 | 1 | NIH | 2/25/2026 | $0 |
| | 2026 | 2022 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057685 | Identifying Suspected Drug Overdose Deaths in Near Real-Time Using Data Collected by Death Investigators | 000 | 1 | NIH | 2/5/2026 | $0 |
| | 2026 | 2022 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057608 | Treating Polysubstance Use in Methadone Maintenance: Application of Novel Digital Technology | 000 | 1 | NIH | 2/9/2026 | $0 |
| | 2026 | 2022 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057685 | Identifying Suspected Drug Overdose Deaths in Near Real-Time Using Data Collected by Death Investigators | 000 | 1 | NIH | 2/5/2026 | $0 |
|
| Issue Date FY: 2025 ( Subtotal = $7,747,769 ) (Continued on the next page) |
| | 2025 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R21DA062508 | Leveraging a time-limited opportunity to study the impact of an intervention for individuals bereaved by drug overdose | 000 | 1 | NIH | 1/30/2025 | $197,250 |
| | 2025 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R33DA059033 | Implementing a patient navigation intervention across a health system to improve outcomes for patients with opioid use disorder | 000 | 2 | NIH | 7/31/2025 | $1,130,715 |
| | 2025 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UM1DA064499 | A patient preference trial of sublingual versus extended-release buprenorphine telemedicine and pharmacy linkage for individuals re-entering the community from jail | 000 | 1 | NIH | 9/5/2025 | $1,393,922 |
| | 2025 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA058674 | A comparative effectiveness trial of sublingual versus extended-release buprenorphine with individuals leaving a carceral setting | 000 | 3 | NIH | 7/18/2025 | $1,129,361 |
| | 2025 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057608 | Treating Polysubstance Use in Methadone Maintenance: Application of Novel Digital Technology | 000 | 2 | NIH | 7/30/2025 | $773,197 |
| | 2025 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056287 | Comparative- and cost-effectiveness research determining the optimal intervention for advancing individuals living with HIV to full viral suppression | 003 | 3 | NIH | 7/18/2025 | $917,615 |
| | 2025 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057685 | Identifying Suspected Drug Overdose Deaths in Near Real-Time Using Data Collected by Death Investigators | 001 | 2 | NIH | 9/18/2025 | $0 |
| | 2025 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057685 | Identifying Suspected Drug Overdose Deaths in Near Real-Time Using Data Collected by Death Investigators | 000 | 2 | NIH | 9/3/2025 | $677,620 |
| | 2025 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057052 | Take-home expansion: Scope and impact study (THESIS) | 000 | 4 | NIH | 7/23/2025 | $633,988 |
| | 2025 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056888 | Optimizing PrEP Implementation and Cost-effectiveness among Individuals with a Substance Use Disorder | 003 | 4 | NIH | 8/1/2025 | $901,066 |
| | 2025 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01NR021987 | A Patient Navigation Trial for Housing and Health (PATHH): A randomized controlled trial | 000 | 1 | NIH | 9/26/2025 | $783,321 |
| | 2025 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R34DA059770 | Addressing racial disparities in opioid overdose deaths using an open source peer recovery coach training and multimodal mobile health platform | 000 | 2 | NIH | 7/25/2025 | $280,478 |
| | 2025 | 2024 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG3DA058305 | Continuing Care App for Justice-Involved Individuals with Substance Use Disorders | 000 | 2 | NIH | 4/10/2025 | $0 |
| | 2025 | 2024 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056287 | Comparative- and cost-effectiveness research determining the optimal intervention for advancing individuals living with HIV to full viral suppression | 004 | 2 | NIH | 7/25/2025 | $534,010 |
| | 2025 | 2024 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056287 | Comparative- and cost-effectiveness research determining the optimal intervention for advancing individuals living with HIV to full viral suppression | 002 | 2 | NIH | 6/27/2025 | $0 |
| | 2025 | 2024 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056287 | Comparative- and cost-effectiveness research determining the optimal intervention for advancing individuals living with HIV to full viral suppression | 001 | 2 | NIH | 6/22/2025 | -$534,010 |
| | 2025 | 2024 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056287 | Comparative- and cost-effectiveness research determining the optimal intervention for advancing individuals living with HIV to full viral suppression | 000 | 2 | NIH | 3/21/2025 | $0 |
| | 2025 | 2024 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056888 | Optimizing PrEP Implementation and Cost-effectiveness among Individuals with a Substance Use Disorder | 001 | 3 | NIH | 6/22/2025 | -$707,335 |
| | 2025 | 2024 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056888 | Optimizing PrEP Implementation and Cost-effectiveness among Individuals with a Substance Use Disorder | 000 | 3 | NIH | 3/21/2025 | $0 |
| | 2025 | 2024 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056888 | Optimizing PrEP Implementation and Cost-effectiveness among Individuals with a Substance Use Disorder | 002 | 3 | NIH | 6/27/2025 | $0 |
|
